LRRIQ1: A K-ELK Enzyme as A Potential Drug Target Or Biomarker

Target Name: LRRIQ1

NCBI ID: G84125

LRRIQ1

LRRIQ1: A K-ELK Enzyme as A Potential Drug Target Or Biomarker

Kallikrein-related peptidases (K-ELKs) are a family of enzymes that regulate various cellular processes in the body, including inflammation, fibrosis, and cancer. K-ELKs play a crucial role in maintaining tissue repair and regeneration, and are often dysregulated in various diseases, including cancer.

LRRIQ1 (KIAA1801) is a K-ELK that has been identified as a potential drug target or biomarker for various diseases. In this article, we will explore the biology of LRRIQ1 and its potential as a drug target.

Biochemistry and Structure

LRRIQ1 is a 21-kDa protein that is expressed in various tissues and organs, including liver, pancreas, and heart. It is a member of the K-ELK family and belongs to the subfamily of 尾-secretase (尾-S) K-ELKs. 尾-S K-ELKs are characterized by the presence of a catalytic core and a 尾-sheet that is responsible for the cleavage of extracellular matrix (ECM) components.

LRRIQ1 has a molecular weight of 17.9 kDa and a calculated pI of 6.3. It has a single transmembrane region that is involved in the cleavage of ECM components. The catalytic core of LRRIQ1 consists of 124 amino acids, while the 尾-sheet is composed of 21 amino acids.

Function and Significance

LRRIQ1 is involved in the regulation of various cellular processes, including cell adhesion, migration, and the turnover of ECM components. It has been shown to play a role in the regulation of tissue repair and regeneration, as well as the development and progression of various diseases.

LRRIQ1 has been shown to be involved in the regulation of extracellular matrix (ECM) component degradation, which is critical for tissue repair and regeneration. ECM components, such as collagen and hyaluronic acid, are involved in the maintenance of tissue structure and function, and are often targeted by enzymes for degradation. LRRIQ1 has been shown to regulate the degradation of ECM components, suggesting that it plays a role in the regulation of tissue repair and regeneration.

LRRIQ1 has also been shown to be involved in the regulation of cell adhesion and migration. Adhesion is the process by which cells stick together to form tissues and organs, and is critical for the development and maintenance of tissues and organs. LRRIQ1 has been shown to play a role in the regulation of cell adhesion and migration by regulating the degradation of ECM components that are involved in these processes.

LRRIQ1 has also been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway. TGF-β is a signaling pathway that is involved in the regulation of cell growth, differentiation, and inflammation. LRRIQ1 has been shown to play a role in the regulation of TGF-β signaling by regulating the degradation of ECM components that are involved in this pathway.

Potential Therapeutic Applications

LRRIQ1 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In cancer, LRRIQ1 has been shown to play a role in the regulation of cell adhesion, migration, and the turnover of ECM components, which are critical for tumor growth and progression. Therefore, LRRIQ1 may be an effective target for cancer therapies that target these processes.

In neurodegenerative diseases, LR

Protein Name: Leucine Rich Repeats And IQ Motif Containing 1

The "LRRIQ1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRIQ1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets